Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer

Fig. 6

Antitumor effects of trastuzumab and BEZ235 on HER2-positive gastric cancer patient-derived xenografts (PDX). The growth of tumors treated with BEZ235 alone or combined with trastuzumab was significantly suppressed both in the NCI-N87 xenografts (a) and in 2 patient-derived xenografts (b and c). BEZ235 combined with trastuzumab imparted synergistically inhibitory effects on the in vivo xenografts (ae). Tumor volumes are expressed as Mean ± S.D. Immunohistochemistry analysis showed that p-AKT, p-S6, and p-ERK were effectively inhibited by BEZ235 combined with trastuzumab compared to BEZ235 alone or trastuzumab alone (f). The scale bar represents 100 μm. P <0.05 by according to repeated measures ANOVA

Back to article page